喘息の治療と管理におけるサルメテロール／フルチカゾン製剤の費用対効果―プロピオン酸フルチカゾンとの比較検討―

DOI Web Site Web Site 参考文献14件
  • 東田 有智
    近畿大学医学部呼吸器・アレルギー内科 NPO法人Japan Asthma and COPD Forum (JASCOM)
  • 西間 三馨
    国立病院機構福岡病院 NPO法人Japan Asthma and COPD Forum (JASCOM)
  • 荒川 一郎
    日本大学薬学部薬事管理学ユニット
  • 白神 誠
    日本大学薬学部薬事管理学ユニット
  • 宮本 昭正
    日本臨床アレルギー研究所 NPO法人Japan Asthma and COPD Forum (JASCOM)

書誌事項

タイトル別名
  • Cost-effectiveness of Salmeterol/Fluticasone Combination Therapy vs. Fluticasone Propionate in Japanese Asthmatic Patients
  • ゼンソク ノ チリョウ ト カンリ ニ オケル サルメテロール フルチカゾン セイザイ ノ ヒヨウ タイ コウカ プロピオンサン フルチカゾン ト ノ ヒカク ケントウ

この論文をさがす

抄録

  We commenced to estimate the economic impact of salmeterol/fluticasone combination (SFC) therapy compared to fluticasone propionate (FP) therapy for asthma control in Japanese patients. A Markov model with five health states, developed by Price in 2002, was used. 1-week transition probabilities among status of asthma management were obtained from literature and epidemiological data from public data base. Direct cost for treatment was estimated from Japan medical fee schedule. Cost and effectiveness were not discounted due to 12-week simulation by the model. Univariate sensitivity analyses were undertaken to examine the main variables affecting cost-effectiveness. Probabilistic analysis was also undertaken to discuss statistical argument and to provide information for decision-making. In this analysis, the model was run over a 12-week period of time using transition probabilities. The results showed that treatment with SFC resulted in a higher proportion of totally controlled weeks per patient than treatment with FP (65.0 vs. 49.5%; incremental effectiveness by 15.5%), and lower mean direct asthma management costs (¥168 702 vs. ¥227 820). Probabilistic sensitivity analysis, conducted to assess robustness of the above base case result, showed that in the 95% of cases SFC was dominant (more effective and less costly) to FP. It suggested that SFC will be the most cost-effective therapy for asthma control. It would, however, be required to further evaluate cost-effectiveness of SFC in long-term observation.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 130 (4), 593-603, 2010

    公益社団法人 日本薬学会

参考文献 (14)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ